tradingkey.logo
tradingkey.logo
Search

Mabwell, Aditum Launch Kalexo Bio To Advance Dual-Target siRNA Therapy For Cardiovascular Disease

ReutersSep 17, 2025 12:18 PM
facebooktwitterlinkedin

- Mabwell Shanghai Bioscience Co Ltd 688062.SS:

  • MABWELL BIOSCIENCE AND ADITUM BIO ANNOUNCE FORMATION OF KALEXO BIO TO ADVANCE INNOVATIVE SIRNA THERAPY FOR CARDIOVASCULAR DISORDERS

  • MABWELL SHANGHAI BIOSCIENCE CO LTD - ELIGIBLE FOR UP TO $1 BILLION IN PAYMENTS

  • MABWELL SHANGHAI BIOSCIENCE CO LTD - GRANTS KALEXO BIO WORLDWIDE RIGHTS TO 2MW7141

  • MABWELL SHANGHAI BIOSCIENCE CO LTD - TO RECEIVE $12 MILLION UPFRONT PAYMENTS AND EQUITY STAKE IN KALEXO BIO

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Recommended Articles

Tradingkey
KeyAI